Digitalni repozitorij raziskovalnih organizacij Slovenije

Iskanje po repozitoriju
A+ | A- | Pomoč | SLO | ENG

Iskalni niz: išči po
išči po
išči po
išči po

Možnosti:
  Ponastavi


Iskalni niz: "avtor" (Zvezdana Hlebanja) .

1 - 10 / 28
Na začetekNa prejšnjo stran123Na naslednjo stranNa konec
1.
Bevacizumab plus chemotherapy in elderly patients with previously untreated metastatic colorectal cancer : single center experience
Janja Ocvirk, Maja Ebert Moltara, Tanja Mesti, Marko Boc, Martina Reberšek, Neva Volk, Jernej Benedik, Zvezdana Hlebanja, 2016, izvirni znanstveni članek

Povzetek: Metastatic colorectal cancer (mCRC) is mainly a disease of elderly, however, geriatric population is underrepresented in clinical trials. Patient registries represent a tool to assess and follow treatment outcomes in this patient population. The aim of the study was with the help of the patients% register to determine the safety and efficacy of bevacizumab plus chemotherapy in elderly patients who had previously untreated metastatic colorectal cancer. Patients and methods. The registry of patients with mCRC was designed to prospectively evaluate the safety and efficacy of bevacizumab-containing chemotherapy as well as selection of patients in routine clinical practice. Patient baseline clinical characteristics, pre-specified bevacizumab-related adverse events, and efficacy data were collected, evaluated and compared according to the age categories. Results. Between January 2008 and December 2010, 210 patients with mCRC (median age 63, male 61.4%) started bevacizumab-containing therapy in the 1st line setting. Majority of the 210 patients received irinotecan-based chemotherapy (68%) as 1st line treatment and 105 patients (50%) received bevacizumab maintenance therapy. Elderly (% 70 years) patients presented 22.9% of all patients and they had worse performance status (PS 1/2, 62.4%) than patients in < 70 years group (PS 1/2, 35.8%). Difference in disease control rate was mainly due to inability to assess response in elderly group (64.6% in elderly and 77.8% in < 70 years group, p = 0.066). The median progression free survival was 10.2 (95% CI, 6.7%16.2) and 11.3 (95% CI, 10.2%12.6) months in elderly and < 70 years group, respectively (p = 0.58). The median overall survival was 18.5 (95% CI, 12.4%28.9) and 27.4 (95% CI, 22.7%31.9) months for elderly and < 70 years group, respectively (p = 0.03). Three-year survival rate was 26% and 37.6% in elderly vs. < 70 years group (p = 0.03). Overall rates of bevacizumab-related adverse events were similar in both groups: proteinuria 21/22 %, hypertension 25/19 %, haemorrhage 2/4 % and thromboembolic events 10/6 %, for elderly and < 70 years group, respectively. Conclusions. In routine clinical practice, the combination of bevacizumab and chemotherapy is effective and welltolerated regimen in elderly patients with metastatic colorectal cancer.
Ključne besede: metastatic colorectal cancer, bevacizumab, chemotherapy, elderly
Objavljeno v DiRROS: 30.04.2024; Ogledov: 186; Prenosov: 56
.pdf Celotno besedilo (620,74 KB)

2.
3.
4.
Priporočila za obravnavo bolnikov z rakom debelega črevesa in danke
2020, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: rak debelega črevesa, rak danke, bolniki, zdravljenje
Objavljeno v DiRROS: 18.03.2022; Ogledov: 910; Prenosov: 490
.pdf Celotno besedilo (1,30 MB)
Gradivo ima več datotek! Več...

5.
6.
Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodca
2021, druge monografije in druga zaključena dela

Povzetek: V Sloveniji vsako leto zboli zaradi raka želodca okrog 450 bolnikov, od tega ima tri četrtine bolnikov ob postavitvi diagnoze razširjeno ali razsejano bolezen. Zato je pomembno, da imamo razvito sodobno multidisciplinarno zdravljenje. Onkološki inštitut je na poti pridobitve evropske onkološke akreditacije, ki jo podeljuje priznana Evropska organizacija onkoloških inštitutov (OECI), katere član je tudi Onkološki inštitut Ljubljana. Namen tega projekta je razvoj kliničnih poti, ki bodo omogočile celostno obravnavo bolnikov z rakom. Slovenskih priporočil za zdravljenje adenokarcinoma želodca trenutno nimamo, zato smo bili primorani sprejeti te, ki jim bomo sledili na Onkološkem inštitutu. V teh priporočilih, zaradi drugačne narave bolezni, ni zajeto zdravljenje raka ezofagogastričnega stika.
Ključne besede: rak želodca, adenokarcinom, onkološko zdravljenje, priporočila
Objavljeno v DiRROS: 14.09.2021; Ogledov: 1481; Prenosov: 395
.pdf Celotno besedilo (983,68 KB)

7.
Rak debelega črevesa in danke : kaj morate vedeti o bolezni
Janja Ocvirk, Vaneja Velenik, Franc Anderluh, Maja Ebert Moltara, Ibrahim Edhemović, Zvezdana Hlebanja, Irena Oblak, Martina Reberšek, 2013, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: rak debelega črevesa, rak danke, zdravljenje, bolniki, priročniki
Objavljeno v DiRROS: 19.03.2021; Ogledov: 1175; Prenosov: 409
.pdf Celotno besedilo (2,31 MB)

8.
Kaj je dobro vedeti o RDČD
Janja Ocvirk, Zvezdana Hlebanja, Neva Volk, Martina Reberšek, Jernej Benedik, Marko Boc, Maja Ebert Moltara, Tanja Mesti, 2013, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Objavljeno v DiRROS: 11.08.2020; Ogledov: 1612; Prenosov: 650
.pdf Celotno besedilo (3,44 MB)

9.
Rak trebušne slinavke : kaj morate vedeti o bolezni?
Janja Ocvirk, Martina Reberšek, Zvezdana Hlebanja, Erik Škof, Irena Oblak, Vaneja Velenik, Franc Anderluh, 2008, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: dejavniki tveganja, simptomi, diagnostika, zdravljenje, bolečina
Objavljeno v DiRROS: 10.08.2020; Ogledov: 1795; Prenosov: 705
.pdf Celotno besedilo (1,52 MB)

10.
Rak požiralnika : kaj morate vedeti o bolezni?
Franc Anderluh, Irena Oblak, Vaneja Velenik, Janja Ocvirk, Zvezdana Hlebanja, Martina Reberšek, Mihael Sok, 2008, slovar, enciklopedija, leksikon, priročnik, atlas, zemljevid

Ključne besede: dejavniki tveganja, simptomi, diagnostika
Objavljeno v DiRROS: 10.08.2020; Ogledov: 1790; Prenosov: 567
.pdf Celotno besedilo (1,34 MB)

Iskanje izvedeno v 0.42 sek.
Na vrh